NRAS Protooncogene, GTPase

Alternative Names

NRAS
Neuroblastoma Ras Viral Oncogene Homolog
Oncogene NRAS
NRAS1

Length

12,303 bases

No. of Exons

No. of isoforms

Protein Name

GTPase NRas

Molecular Mass

21229 Da

Amino Acid Count

189

Genomic Location

chr1:114,704,468-114,716,770

Gene Map Locus

1p13.2

Description

This is an N-ras oncogene encoding a membrane protein that shuttles between the Golgi apparatus and the plasma membrane. This shuttling is regulated through palmitoylation and depalmitoylation by the ZDHHC9-GOLGA7 complex. The encoded protein, which has intrinsic GTPase activity, is activated by a guanine nucleotide-exchange factor and inactivated by a GTPase activating protein. Mutations in this gene have been associated with somatic rectal cancer, follicular thyroid cancer, autoimmune lymphoproliferative syndrome, Noonan syndrome, and juvenile myelomonocytic leukemia. [From RefSeq]

Epidemiology in the Arab World

View Map

Variant Name	Country	Genomic Location	Clinvar Clinical Significance	CTGA Clinical Significance	Condition(s)	HGVS Expressions	dbSNP	Clinvar
NM_002524.5:c.181C>A	Lebanon	NC_000001.11:g.114713909G>T	Drug Response, Likely Pathogenic, Pathogenic, Uncertain Significance	Likely Pathogenic	Thyroid Carcinoma, Papillary	NG_007572.1:g.7986C>A; NM_002524.5:c.181C>A; NP_002515.1:p.Gln61Lys	121913254	73058
NM_002524.5:c.182A>G	Lebanon	NC_000001.11:g.114713908T>C	Likely Pathogenic, Pathogenic			NG_007572.1:g.7987A>G; NM_002524.5:c.182A>G; NP_002515.1:p.Gln61Arg	11554290	13900
NM_002524.5:c.34G>A	Lebanon	NC_000001.11:g.114716127C>T	Likely Pathogenic, Pathogenic	Likely Pathogenic	Thyroid Carcinoma, Papillary	NG_007572.1:g.5768G>A; NM_002524.5:c.34G>A; NP_002515.1:p.Gly12Ser	121913250	177778
NM_002524.5:c.38G>A	Lebanon	NC_000001.11:g.114716123C>T	Likely Pathogenic, Pathogenic	Likely Pathogenic	Thyroid Carcinoma, Papillary	NG_007572.1:g.5772G>A; NM_002524.5:c.38G>A; NP_002515.1:p.Gly13Asp	121434596	13901

Download Table

Other Reports

Arab

Al-Shamsi et al. 2021 delineated the somatic mutational spectrum and frequency in Arab women with breast cancer. 78 women mostly with stage 3 or 4 breast cancer exhibited mutations and mutation rates in the following genes: TP53, 23.1%; ATM, 2.6%; IDH1, 2.6%; IDH2, 3.8%; PTEN, 7.7%; PIK3CA, 15.4%; APC, 7.7%; NPM1, 2.5%; MPL, 1.3%; JAK2, 2.5%; KIT, 7.7%; KRAS, 3.8%; and NRAS, 3.8%

External Links

https://medlineplus.gov/genetics/gene/nras/ https://www.genecards.org/cgi-bin/carddisp.pl?gene=nras

Contributors

Sami Bizzari: 23.02.2022
Pratibha Nair: 09.05.2021

Edit History

Sami Bizzari: 23.02.2022
Pratibha Nair: 09.05.2021

Back to search Result